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Increased expression of protease-activated receptor 1 (PAR1), a G protein-coupled receptor for thrombin,
has previously been correlated with breast carcinoma cell invasion. PAR1 is irreversibly proteolytically
activated, internalized, and sorted directly to lysosomes, a critical process for the termination of signaling. We
determined that activated PAR1 trafficking is severely altered in metastatic breast carcinoma cells but not in
nonmetastatic or normal breast epithelial cells. Consequently, the proteolytically activated receptor is not
sorted to lysosomes and degraded. Altered trafficking of proteolytically activated PAR1 caused sustained
activation of phosphoinositide hydrolysis and extracellular signal-regulated kinase signaling, even after throm-
bin withdrawal, and enhanced cellular invasion. Thus, our results reveal that a novel alteration in trafficking
of activated PAR1 causes persistent signaling and, in addition to other processes and proteins, contributes to
breast carcinoma cell invasion.
The genetic changes that initiate tumor cell metastasis and
invasion are unclear. The procoagulant activities of tumor cells
and surrounding stromal cells that lead to thrombin generation
and fibrin deposition appear to provide an important influence
on tumor cell invasion and metastasis (3). Although a link
between coagulation factors and tumor progression and me-
tastasis has been firmly established, the molecular basis re-
mains poorly understood (7, 26).
Thrombin, the main effector protease of the coagulation
cascade, is generated by the actions of tissue factor and other
coagulation factors. The first description of thrombin-induced
murine tumor cell metastasis was provided by Nierodzik and
colleagues (23, 24). Subsequent studies determined that tissue
factor, like thrombin, is highly expressed in carcinoma cells and
contributes to metastasis (20, 21). In addition, the anticoagu-
lants heparin and warfarin have been shown to significantly
decrease experimentally induced pulmonary metastasis in vivo
(37). A similar decrease in tumor cell metastasis in vivo was
observed with hirudin, a specific inhibitor of thrombin (9).
Fibrin, generated by the action of thrombin on fibrinogen, is a
significant component of the tumor microenvironment and has
been strongly associated with tumor progression and metasta-
sis (7). A recent genetic study revealed that, in fibrinogen-
deficient mice, the development of both spontaneous and
experimental lung metastases was substantially diminished
(27). However, hirudin further diminished the metastatic po-
tential of tumor cells in fibrinogen-deficient mice. Thus, while
fibrinogen is one critical component of metastasis, thrombin
appears to contribute to tumor cell dissemination through at
least one fibrinogen-independent mechanism.
In addition to acting on fibrinogen, thrombin elicits a host of
cellular responses through the activation of G protein-coupled
protease-activated receptors (PARs): PAR1, -3, and -4 (6).
Thrombin activation of PAR1 mediates proliferative signaling
and migratory responses in a variety of cell types (19, 29). A
role for PAR1 in tumor cell invasion is suggested by increased
PAR1 mRNA and protein expression in infiltrating ductal car-
cinomas of breast tissue specimens and in highly invasive
breast carcinoma cell lines; these increases have been corre-
lated with carcinoma cell invasiveness (10, 13). Importantly,
the addition of thrombin further increased the invasiveness of
certain breast carcinoma cells but had no effect on noninvasive
cells. In contrast, PAR1 expression was minimal or absent in
premalignant atypical intraductal hyperplasia, normal breast
epithelial tissue specimens, and noninvasive cell lines, as well
as the B16F10 cell line (10, 13). Additionally, antisense inhi-
bition of PAR1 expression in a highly invasive breast carci-
noma cell line caused a reduction in invasive potential (10, 22).
Thus, the roles of thrombin and PAR1 and the mechanism by
which they contribute to breast carcinoma cell invasion remain
poorly understood.
PAR1 is activated by an unusual proteolytic mechanism in
which thrombin binds to and cleaves the amino-terminal exo-
domain of the receptor (6). This cleavage generates a new
amino terminus that functions as a tethered ligand by binding
intramolecularly to the body of the receptor to cause trans-
membrane signaling. Because proteolytic activation of PAR1
creates a tethered ligand that cannot diffuse away, the mech-
anisms that contribute to the termination of receptor signaling
are critical in determining the magnitude and duration of
thrombin-stimulated signaling in cells.
Signaling by activated PAR1 is terminated at the plasma
membrane by phosphorylation and arrestin binding (15, 25).
However, we demonstrated previously that downregulation of
activated PAR1 by internalization and lysosomal sorting is also
critical for the termination of receptor signaling. In fibroblasts,
a chimeric PAR1 that internalizes and recycles back to the cell
surface showed enhanced and prolonged signaling after acti-
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vation with thrombin (35, 36). This prolonged signaling was
apparently due to recycling and continued signaling by proteo-
lytically activated receptors that returned to the plasma mem-
brane with their tethered ligands intact. In the present study,
we determined that activation of PAR1 is necessary and suf-
ficient for thrombin-stimulated breast carcinoma cell invasion
and that dysregulated PAR1 trafficking leads to constitutive
signaling and promotes cellular invasion.
MATERIALS AND METHODS
Plasmid constructs. A human PAR1 cDNA sequence was isolated by PCR
from a human colon cDNA library (Clontech), sequence verified, and subcloned
into the pBabe-puro expression vector. PCR amplification was used to generate
a PAR1 cDNA in antisense orientation representing the first exon, as previously
described (11), which was subcloned into pBabe-puro. A chimeric PAR1 bearing
the substance P receptor carboxyl-terminal tail (P/S C tail) was described previ-
ously (35).
Materials and antibodies. The PAR1 agonist peptide SFLLRN was synthe-
sized at the Chapel Hill Peptide Facility, University of North Carolina. Human
-thrombin (Enzyme Research Laboratories), pertussis toxin (Calbiochem),
leech hirudin, -trypsin treated with tosyl-amido-2-phenylethyl chloromethyl ke-
tone, and trypsin inhibitor (Sigma) were from commercial sources.
A rabbit polyclonal anti-PAR1 antibody was generated as described previously
(14). Monoclonal anti-PAR1 antibody (Biodesign International), anti-p42/44
(Santa Cruz Biotechnology), anti-phospho-p42/44 ERK antibodies (Cell Signal-
ing Technology), and EEA1 antibody (Transduction Laboratories) were pur-
chased from commercial sources. Anti-LAMP1 H4A3 monoclonal antibody was
obtained from the Developmental Studies Hybridoma Bank maintained by the
University of Iowa. The secondary antibodies, goat anti-mouse and anti-rabbit
conjugated to horseradish, were from Pierce. Alexa488- and Alexa594-conju-
gated goat anti-mouse and anti-rabbit antibodies were from Molecular Probes.
Cell culture. All human breast carcinoma cell lines were obtained from the
American Type Culture Collection (ATCC) and were maintained in growth
media as recommended by ATCC. HeLa cells stably expressing PAR1 or the P/S
C tail were generated and characterized as described previously (33). HEK 293T
cells were maintained in growth medium as recommended by ATCC. Human
mammary epithelial cells (HMECs) immortalized by ectopic expression of the
catalytic subunit of hTERT were kindly provided by Robert Weinberg (Massa-
chusetts Institute of Technology) and were maintained as described previously
(8).
Retroviral infection and transfection. Infectious amphotropic recombinant
retrovirus encoding PAR1 or the empty vector was produced in HEK 293T cells
using the pVPack retroviral production system (Stratagene) as described previ-
ously (28). Cells were infected with retroviral supernatant, and mass cell popu-
lations were selected in medium containing 1 g of puromycin/ml.
Cellular invasion assay. Cellular invasion was assessed using a procedure
modified from that previously described (1). Serum-starved invasive (2,000 to
5,000) or noninvasive (5  104 to 2  105) breast carcinoma cells were diluted in
500 l of Dulbecco’s minimum essential medium (DMEM) containing 0.1%
bovine serum albumin (BSA) with or without agonists and were added to the
upper well. The peptide agonist SFLLRRN or -thrombin (-Th) was added to
the cells in the upper well in order to completely activate PAR1. The assays were
performed in this manner to directly assess whether proteolytic activation of
PAR1 promotes cellular invasion and to allow interpretation in a consistent and
reproducible manner. Hence, -Th and the peptide agonist were utilized as
stimulators of movement, not chemoattractants, in invasion assays (11, 13). Since
for the majority of our assays the stimulus was present in the upper and not the
lower chamber, some aspect of our assayed invasion might also have been
contributed by chemokinesis in response to a reverse gradient. However, since
we also observed PAR1-dependent migration in the absence of ligand, we believe
that the observed invasion activity was due primarily to PAR1 activation.
In the initial assays that were performed to optimize the assay, it was difficult
to interpret in a consistent and reproducible manner whether thrombin stimu-
lation of PAR1 increased breast carcinoma cell invasion, because too many cells
invaded the Matrigel when the medium in the lower chamber contained serum
or any type of adhesive ligand. Therefore, the Boyden chamber assay was opti-
mized by manipulating the percentage of serum in the bottom well and the
density of serum-starved cells plated in the upper well. Thus, serum-free medium
containing 0.1% BSA (750 l) was added to the lower well and cells were
incubated for 24 h at 37°C. The filters were fixed and stained with hematoxylin
and eosin. The cells on 50% of the membrane area were counted using a 10
objective, and the cells in the bottom well were counted using a hemocytometer.
RT-PCR. Total RNA was isolated from cells using TRI-reagent (MRC) ac-
cording to the manufacturer’s instructions. PAR1 mRNA was PCR amplified
using a sense-strand primer (5 CAG TTT GGG TCT GAA TTG TGT CG 3)
and an antisense primer (5 TGC ACG AGC TTA TGC TGC TGA C 3) as
described previously (17). The antisense primer was used in the reverse-tran-
scription (RT) step, and the resulting PCR product contained 591 bases. 18S
rRNA was amplified simultaneously using the Alternate 18S Internal Standards
primer set (Ambion) and served as an internal loading control. PCR products
were resolved by sodium dodecyl sulfate–8% polyacrylamide gel electrophoresis
(SDS–8% PAGE), and dried gels were imaged by autoradiography.
Immunoprecipitation and immunoblotting. To assess PAR1 protein expres-
sion, 50 g of total cell lysate protein was resolved by SDS-PAGE, followed by
immunoblot analyses with anti-PAR1 antibody. To assess PAR1 degradation,
cells were plated at a density of 106 per 100-mm-diameter plate; grown overnight;
serum starved for 30 min in DMEM supplemented with 1 mg of BSA/ml, 10 mM
HEPES, and 10 M cycloheximide; and then stimulated with 50 M peptide
agonist for 120 min. The cells were washed, lysed in 1% Triton X-100 buffer,
immunoprecipitated with a mouse monoclonal PAR1 antibody, and immuno-
blotted as described previously (25). The immunoblots were developed and
imaged by autoradiography.
ERK activity was assayed in cells serum starved for 48 to 72 h. During the
starvation period, the serum-free medium was replaced every 24 h. The cells
were stimulated with 10 nM -Th for appropriate times, equivalent amounts of
lysates were resolved by SDS-PAGE, and ERK activity was assayed by immu-
noblot analyses with an anti-phospho-p42/44 ERK antibody. The membranes
were then reprobed with anti-p42/44 antibody to quantitate total ERK expres-
sion.
Internalization and recycling assays. Internalization and recycling of activated
PAR1 were assessed essentially as described previously (36). Briefly, 6  105
breast carcinoma cells were aliquoted into 1.7-ml microcentrifuge tubes and
incubated with anti-PAR1 antibody for 1 h at 4°C. The cells were agonist treated,
washed, and incubated with 200 nM trypsin for 30 min at 4°C to remove receptor-
antibody complex that remained on the cell surfaces. The cells were then washed
and incubated in medium containing 2 g of trypsin inhibitor/ml, and the reap-
pearance of receptor-antibody complex on the cell surface was determined after
30 min. The amount of receptor-bound antibody on the cell surface was quan-
titated at various times by enzyme-linked immunosorbent assay.
Confocal microscopy. Cells grown on fibronectin-coated glass coverslips (22 by
22 mm) were incubated with or without agonists, fixed, immunostained for PAR1
and either LAMP1 or EEA1, washed, incubated with species-specific fluoro-
phore-conjugated secondary antibodies, and examined by confocal microscopy as
previously described (38).
Phosphoinositide (PI) hydrolysis assay. Breast carcinoma cells (106) plated on
100-mm-diameter dishes were labeled overnight with 1 Ci of [myo-3H]inositol
(American Radiochemicals)/ml in inositol-free DMEM containing 1 mg of BSA/
ml. The cells were removed, aliquoted (6  105) into 1.7-ml microcentrifuge
tubes, washed, and agonist treated, and the accumulation of inositol phosphates
(IPs) was measured as described previously (36).
RESULTS
Activation of PAR1 enhances invasion of breast carcinoma
cells. Increases in PAR1 mRNA and protein expression have
been correlated with invasiveness of certain breast carcinoma
tumors and cell lines (10, 13, 24). However, the role of PAR1
activation and the mechanism by which it contributes to cellu-
lar invasion are poorly understood. To determine a role for
proteolytically activated PAR1 in cellular invasion, we first
examined a series of human mammary carcinoma cell lines for
PAR1 protein expression and determined the basal invasive
potential by examining the ability of cells to migrate through a
reconstituted basement membrane. We performed our assays
essentially as described previously (11, 13), with thrombin
added to the upper well to stimulate PAR1 activation.
The normal MCF-10A and noninvasive MDA-MB-468,
T47D, MCF-7, SKBr3, and Zr-75-1 human breast carcinoma
cell lines and the noninvasive hTERT-immortalized normal
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HMECs did not show significant PAR1 protein expression
(data not shown) or exhibit cellular invasion (Fig. 1). In con-
trast, MDA-MB-231 cells, a highly invasive cell line, expressed
an elevated level of PAR1 in comparison to the noninvasive
MCF-7 cells (Fig. 1). Similarly, PAR1 protein overexpression
also correlated with the invasive capabilities of the BT549 and
Hs578T cell lines (Fig. 1). Interestingly, ectopic overexpression
and proteolytic activation of PAR1 in HMECs, a normal breast
epithelial cell line, did not induce in vitro invasion (Fig. 1B).
However, ectopic overexpression and activation of PAR1 in
MCF-7 cells, a normally noninvasive breast carcinoma cell line,
induced a significant increase in cellular invasion (data not
shown). These studies demonstrate that mere overexpression
and activation of PAR1 in normal breast epithelial cells is not
sufficient to induce invasive potential, suggesting the likelihood
that perturbations in other cellular processes and proteins in
these breast carcinoma cells likely contribute to cellular
invasion. However, these findings do confirm the studies of
Nierodzik et al. (22) with B16F10 cells and experimental me-
tastasis and further support the possibility that activation of
overexpressed PAR1 in invasive breast carcinoma cell lines
contributes to cellular invasion. To investigate this possibility,
we used the invasive MDA-MB-231, BT549, and Hs578T cells
and the noninvasive hTERT-immortalized normal HMECs to
assess a causal relationship between PAR1 overexpression and
invasion.
To investigate whether PAR1 overexpression and activation
contribute to breast carcinoma cell invasion, we ectopically
overexpressed an antisense cDNA construct of PAR1 (10) in
Hs578T, BT549, and MDA-MB-231 human breast carcinoma
cell lines. RT-PCR revealed a decrease in PAR1 mRNA ex-
pression in the antisense-expressing cells compared to vector
controls (Fig. 2A). Immunoblot analysis of lysates from anti-
sense-expressing cells confirmed the stable reduction of PAR1
protein expression, whereas expression of the receptor was
retained in vector controls. The empty-vector control popula-
tions of Hs578T, BT549, and MDA-MB-231 cells retained
ligand-dependent stimulation (three- to fourfold) of invasion
in response to thrombin (Fig. 2B). However, in cells expressing
the PAR1 antisense-cDNA construct, thrombin-mediated ac-
tivation of PAR1-induced cellular invasion was significantly
decreased (Fig. 2B). Taken together, these data strongly sug-
gest that thrombin activation of PAR1 enhances breast carci-
noma cell invasion in vitro. However, downregulation of PAR1
FIG. 1. PAR1 protein is overexpressed in invasive breast carcinoma cell lines. (A) Lysates prepared from multiple breast carcinoma cell lines
were resolved by SDS–15% PAGE (50 g of total protein), transferred, and immunoblotted with an anti-PAR1 monoclonal antibody. Immuno-
blotting these same membranes for total ERK with a polyclonal anti-p42/44 ERK antibody served as a control for equal loading. (B) Basal invasion
activity of breast carcinoma cell lines was measured using a Matrigel invasion assay. All of the cell lines were serum starved for a minimum of 24 h,
and cellular invasion was assessed by the addition of -Th to the upper well only to stimulate PAR1 activation. The data are expressed as the
percentage of cells that invaded compared to the total number of cells seeded in the upper chamber and are reported as the mean percentage plus
the standard error of the mean of at least two independent experiments for MCF10A, HMEC-PAR1, and T47D cells; three independent
experiments for MCF-7 and SKBR3 cells; and six independent experiments for MDA-MB-231, Hs578T, and BT549. The average numbers of cells
invading under basal conditions in a given experiment were between 0 and 100 cells for MCF-10A, T47D, MCF-7, HMEC-PAR1 and SKBr3 and
between 200 and 600 cells for MDA-MB-231, BT549, and Hs578T.
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expression did not appear to inhibit the basal invasive activity
of the invasive breast carcinoma cell lines, which is consistent
with the likelihood that the altered functions of other proteins
also contribute to invasion by these breast carcinoma cells.
Activated PAR1 is not degraded in invasive breast carci-
noma cells. To determine if differences in PAR1 degradation
may account for altered PAR1 protein levels in invasive breast
carcinoma cells, we examined whether PAR1 was efficiently
degraded in these cells. In HMECs that ectopically overex-
pressed PAR1 protein (HMEC-PAR1), we observed that pro-
longed exposure to SFLLRN agonist peptide caused a signif-
icant loss (25% remaining) of PAR1 protein (Fig. 3A), similar
to that observed in fibroblasts and HeLa cells (33, 34). In
striking contrast, the same treatment of Hs578T, BT549, and
MDA-MB-231 cells with SFLLRN showed reduced degrada-
tion of endogenous PAR1 and retained 60 to 70% of receptor
protein (Fig. 3A). These findings suggest that activated PAR1
is unable to undergo efficient degradation in invasive breast
carcinoma cells.
Aberrant trafficking of activated PAR1 in invasive breast
carcinoma cells. To determine whether the failure of activated
PAR1 to be efficiently downregulated was due to an inability of
the receptor to be internalized, we examined agonist-induced
loss of cell surface PAR1. Thrombin treatment of PAR1-ex-
pressing HMECs induced rapid and substantial internalization
of PAR1 (Fig. 4A), similar to reported studies using fibroblasts
and HeLa cells (33, 34). In striking contrast, the same treat-
ment of Hs578T, BT549, and MDA-MB-231 cells induced a
markedly low rate of internalization and only a modest loss (20
to 25%) of endogenous PAR1 from the cell surface following
FIG. 2. Expression and activation of PAR1 enhances thrombin-mediated breast carcinoma cell invasion. (A) Lysates prepared from cells stably
expressing PAR1 antisense (as) cDNA or empty vector (vec) were resolved by SDS-PAGE (50 g of total protein) and immunoblotted using a
monoclonal PAR1 antibody. RT-PCR was used to assess PAR1 mRNA levels in antisense and vector control-expressing cells, and 18S mRNA was
amplified as a control. (B) MDA-MB-231, BT549, and Hs578T cells expressing empty vector or PAR1 antisense cDNA were serum starved for a
minimum of 24 h and then incubated in the absence or presence of 10 nM -Th, and cellular invasion was assessed. The data are expressed as the
increase (n-fold) in cells invaded compared to untreated controls and represent the means plus standard errors of the mean of at least three
independent experiments. The average numbers of cells invading after stimulation with 10 nM -Th in a given experiment were between 0 and 20
for HMEC-PAR1 and between 600 and 1,100 for MDA-MB-231, BT549, and Hs578T.
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60 min of agonist exposure. These data suggest that the im-
paired degradation of PAR1 seen in invasive breast carcinoma
cells (Fig. 3A) is due in part to a defect in trafficking of PAR1.
The failure of activated PAR1 to efficiently internalize in
invasive cells could be due to slowed internalization or recy-
cling of internalized receptor back to the cell surface. To di-
rectly test whether activated PAR1 was recycled, we examined
the recovery of previously internalized receptor to the cell
surface (36). Exposure of HeLa-PAR1 cells to SFLLRN
caused substantial internalization of receptor from the cell
surface (Fig. 4B); however, little recovery of receptor (3%) was
detected despite the substantial amount that had been inter-
nalized previously (Fig. 4C). In contrast, substantial recovery
(25%) of receptor-bound antibody was seen in agonist-
treated HeLa cells expressing a chimeric PAR1 bearing the P/S
C tail, which undergoes internalization and recycling rather
than lysosomal degradation, as was previously reported (35,
36). The addition of SFLLRN caused a more modest decrease
in PAR1 from the cell surface in Hs578T, BT549, and MDA-
MB-231 cells (Fig. 4B), consistent with the extent of PAR1
internalization induced by thrombin (Fig. 4A). Interestingly,
little recovery of receptor (3%) was detected in Hs578T cells.
However, BT549 and MDA-MB-231 cells pretreated with ag-
onist showed significant recovery (12 to 18%) of previously
internalized PAR1 (Fig. 4C). These data are consistent with
agonist-dependent internalization and recycling, rather than
degradation, of PAR1 in BT549 and MDA-MB-231 cells.
We next determined whether the ability of activated PAR1
to be internalized and sorted to lysosomes was altered in breast
carcinoma cells. For these analyses, we examined the traffick-
ing of internalized PAR1 after prolonged agonist treatment by
using immunofluorescence confocal microscopy. HMEC-PAR1
cells were used as a control to assess the trafficking of PAR1 in
normal breast epithelial cells. PAR1 was located predomi-
nantly at the cell surface in unstimulated HeLa cells and
HMECs (Fig. 5A). After 30 min of agonist stimulation, PAR1
was robustly internalized to endocytic vesicles and markedly
colocalized with EEA1, a specific marker of early endosomes
(4). However, after prolonged agonist treatment, PAR1-con-
taining endosomes were no longer apparent, whereas EEA1
localization was not perturbed, suggesting that activated PAR1
is sorted to a degradative pathway in these cells.
In unstimulated MDA-MB-231 cells, endogenous PAR1 was
found on the cell surface and also partially in an intracellular
compartment (Fig. 5B). As reported previously (30), this dis-
tribution pattern is consistent with tonic cycling of inactivated
PAR1 between the cell surface and an intracellular compart-
ment. Upon agonist stimulation, PAR1 was redistributed from
the cell surface and was found to be localized predominantly in
enlarged early endosomes (Fig. 5B). However, after prolonged
agonist exposure, PAR1 remained localized in enlarged early
endosomes and failed to sort to a degradative compartment. In
BT549 and Hs578T cells, agonist treatment also caused PAR1
to localize to endocytic vesicles and failed to induce the redis-
tribution of receptor to a degradative compartment. Consistent
with the lack of receptor degradation in stimulated MDA-MB-
231 and BT549 cells, activated PAR1 failed to colocalize with
lysosome-associated membrane protein 1 (LAMP1), a marker
of late endosomes and lysosomes (Fig. 5C). A similar lack of
colocalization of activated PAR1 with LAMP1 was also ob-
served in stimulated Hs578T cells. This distribution in breast
carcinoma cells contrasts with that seen in HMECs, in which
activated PAR1 showed significant colocalization with LAMP1
after 60 min of agonist exposure.
Persistent signaling by activated PAR1 induces invasion by
breast carcinoma cells. We next determined whether altered
trafficking of activated PAR1 resulted in aberrant signaling in
invasive cells. It is conceivable that proteolytically activated
PAR1 can continue to signal if it remains on the cell surface or
if it is internalized and recycled back to the cell surface with its
tethered ligand intact. Therefore, we examined whether acti-
vation of PAR1 with thrombin or SFLLRN induced persistent
signaling in invasive cells by assaying for the accumulation of
IPs after agonist removal. In HeLa- and HMEC-PAR1 cells,
PAR1 signaling to PI hydrolysis ceased rapidly (90% shutoff)
following the removal of either thrombin or SFLLRN (Fig.
6A), and this rapid shutoff is consistent with the extent of
shutoff in PAR1 signaling observed in fibroblasts (36). Inter-
estingly, SFLLRN-stimulated carcinoma cells also showed a
substantial (70 to 80%) shutoff in signaling by PAR1 following
the removal of this peptide agonist. However, in striking con-
trast to HeLa cells and HMECs, when activated by thrombin,
the breast carcinoma cell lines showed significant defects (20 to
50%) in the ability to shut off signaling in the absence of
thrombin. Thus, in contrast to normal breast epithelial cells,
proteolytically activated PAR1 signals persistently in invasive
breast carcinoma cells after thrombin withdrawal.
Thrombin stimulation also causes PAR1 activation of the
p42/p44 extracellular signal-regulated kinase (ERK) pathway
(34), an important mitogenic signaling cascade. Therefore, we
determined whether PAR1 activation of ERK is altered in
breast carcinoma cells. Thrombin treatment of HMECs caused
a robust and transient activation of ERK, with peak activation
at 15 min followed by a rapid decrease by 30 min (Fig. 6B), a
FIG. 3. Defective degradation of activated PAR1 in invasive breast carcinoma cell lines. Cells plated at a density of 106 were incubated in the
absence (0) or presence (120) of 50 M SFLLRN for 120 min at 37°C. The cells were lysed and immunoprecipitated (IP) with monoclonal
anti-PAR1 antibody. The immunoprecipitates were resolved by SDS–9% PAGE, transferred, and immunoblotted (IB) with an anti-PAR1
polyclonal antibody.
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time course seen previously in other cell types (16, 34). In
contrast, thrombin treatment of Hs578T and BT549 cells
clearly caused a rapid and sustained (60- to 120-min) activation
of ERK. However, thrombin stimulation of MDA-MB-231
cells also induced a rapid activation of ERK with a peak at 15
min. As a result of the high basal phosphorylation state of
ERK, which is a consequence of the MDA-MB-231 cells ha-
boring an activated K-Ras allele (12), it is not clear if thrombin
stimulation induces sustained activation of ERK in MDA-MB-
231 cells. Taken together with the PI analyses, these results
suggest that proteolytically activated PAR1 signaling is sus-
tained in invasive breast carcinoma cells even in the absence of
thrombin.
We next determined whether proteolytically activated PAR1
was able to promote cellular invasion after the removal of
thrombin in the invasive breast carcinoma cell lines. To eval-
uate this possibility, cells were preincubated initially with
thrombin or SFLLRN. The stimulus was then removed, and
the cells were evaluated for invasive potential. The continuous
exposure to thrombin or SFLLRN induced three- to fourfold
increases in cellular invasion (Fig. 6C), results consistent with
those shown in Fig. 2. As expected, cellular invasion was not
induced following incubation and the removal of SFLLRN. In
striking contrast, significant increases (2.5- to 3-fold) in inva-
sion were observed in cells after incubation and the removal of
thrombin. Taken together, these data suggest that continued
signaling by proteolytically activated PAR1 promotes cellular
invasion.
DISCUSSION
In this study, we demonstrate that thrombin activation of
PAR1 in breast carcinoma cell lines, but not normal breast
epithelial cell lines, causes constitutive signaling and contrib-
utes in part to breast carcinoma cell invasion. The proteolytic
activation of PAR1 by thrombin resulted in continued signal-
ing, even after thrombin withdrawal, and promoted cellular
invasion. This persistent signaling by proteolytically activated
PAR1 in specific breast carcinoma cell lines appears to be
caused by slowed internalization and/or recycling and a lack of
lysosomal degradation of activated receptors rather than ab-
errant translation. These defects were specific for breast car-
cinoma cells, as PAR1 overexpression in other cells (HMEC-
PAR1 and HeLa-PAR1) produced normal receptor trafficking
and shutoff of signaling. Previously, the prolonged G protein-
coupled receptor (GPCR) signaling observed in human can-
cers has been attributed to mutational activation of the GPCR
or the G subunit, increased gene expression or splicing, or
upregulation of ligand expression (18, 39). Our study reveals a
novel gain-of-function mechanism for the aberrant activation
of GPCR signaling in certain human cancer cells.
The failure to efficiently downregulate activated PAR1 by
internalization and lysosomal sorting suggests that increased
PAR1 protein expression observed in invasive breast carci-
noma cells is due partially to defective receptor trafficking.
Though gene mutations acquired during tumorigenesis could
lead to increased stability of the receptor protein or constitu-
tive activity, we found no missense mutations in the endoge-
nous PAR1 coding sequence. Furthermore, while the duplica-
tion and/or amplification of genes is commonly seen in tumor
cells, our analysis by RT-PCR of PAR1 mRNA expression
showed comparable transcript levels in various invasive breast
cell lines, yet we observed considerable differences in PAR1
protein expression (Fig. 1A). Based on receptor degradation
FIG. 4. Agonist-induced internalization and recycling of PAR1 are
perturbed in invasive breast carcinoma cells. (A) Cells were incubated
in the absence or presence of 10 nM -Th for the indicated times at
37°C and fixed, and the amount of PAR1 remaining on the cell surface
was measured by enzyme-linked immunosorbent assay. The results are
expressed as the mean percentage ( standard error of the mean
[SEM]) of total antibody bound to untreated controls in two separate
experiments in which duplicate determinations were made. (B and C)
Cells labeled with anti-PAR1 antibody were incubated in the absence or
presence of 50 M SFLLRN for 60 min. The cells were then trypsin
treated, and the amount of receptor-bound antibody reappearing at the
cell surface was measured after 30 min. The amount of antibody re-
maining on the cell surface following trypsin treatment was between 2
and 8% of total binding and was subtracted to obtain the values shown.
The results are the amounts of surface-bound antibody detected after
agonist incubation at 37°C (B) and after 30 min of recovery (C) and are
expressed as the mean percentages (SEM) of total antibody bound to
untreated control cells.
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studies we performed in the presence of cycloheximide (Fig.
3A), these differences in protein expression appear not to be
attributable to alterations in PAR1 translation. Finally, dys-
regulated lysosomal sorting of activated PAR1 in breast carci-
noma cells is unlikely to be due to a general defect in the
trafficking machinery, since intracellular trafficking of trans-
ferrin and low-density lipoprotein, as well as lysosomal sorting
of LAMP1, are unperturbed. Together, these findings suggest
FIG. 5. PAR1 trafficking is dysregulated in invasive breast carcinoma cells. (A) HeLa- and HMEC-PAR1 cells were preincubated with
anti-PAR1 antibody at 4°C, washed, and then incubated in the absence (Control) or presence of 50 M SFLLRN for 30 or 120 min at 37°C. The
cells were fixed, permeabilized, and immunostained for PAR1 (green) and EEA1 (red). (B) MDA-MB-231 and BT549 cells were treated as
described for panel A. (C) Cells labeled with anti-PAR1 antibody were agonist treated for either 60 or 120 min and then coimmunostained for
PAR1 (green) and lysosomal marker protein LAMP1 (red). The images are representative of 100 cells examined in at least three independent
experiments. The insets are magnifications of the boxed areas. Scale bar, 19.4 m. Arrows indicate staining of PAR1-positive intracellular vesicles.
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that alterations in gene expression are not solely responsible
for PAR1 overexpression and that specific defects in receptor
trafficking are also a contributing factor.
There are three temporally distinct processes that mediate
termination of PAR1 signaling: desensitization, internaliza-
tion, and downregulation. PAR1 signaling was efficiently shut
off when it was reversibly activated by the agonist peptide
SFLLRN in invasive breast carcinoma cells. This suggests that
PAR1 desensitization, phosphorylation, and rapid uncoupling
from signaling are likely intact in invasive carcinoma cells. It is
possible that sustained signaling is due in part to dramatically
slowed internalization of activated PAR1, which continues to
signal from the cell surface. However, we showed that agonist
stimulation promoted PAR1 internalization and caused the
redistribution of activated PAR1 to early endosomes in inva-
sive cells. An alternative mechanism for constitutive signaling
by activated PAR1 is internalization followed by recycling of
proteolytically activated receptors back to the cell surface.
Consistent with this hypothesis, we observed significant recov-
ery of previously internalized PAR1 to the cell surface follow-
ing agonist removal in invasive BT549 and MDA-MB-231 cells.
Moreover, we found that internalized PAR1 remained in en-
dosomes and failed to colocalize with the lysosomal marker
protein LAMP1 even after prolonged agonist exposure. Fi-
nally, an additional mechanism for constitutive signaling by
activated PAR1 is signaling from activated receptors in endo-
FIG. 6. Persistent signaling by activated PAR1 promotes invasion by breast carcinoma cell lines. (A) Cells labeled with [myo-3H]inositol were
incubated with 50 M SFLLRN or 10 nM -Th for 60 min at 37°C in the absence of LiCl. Agonists were removed, and the cells were washed with
DMEM containing 0.5 U of hirudin/ml and incubated with DMEM (20 mM LiCl and hirudin) at 37°C for an additional 60 min, at which time
accumulated 3H-labeled IPs were measured. The results shown are normalized to the amount of IP species generated when agonist was added with
LiCl and are expressed as the mean percent (plus standard error of the mean [SEM]) shutoff of at least two separate experiments. (B) Cells were
serum starved for 48 to 72 h and incubated in the presence or absence of 10 nM -Th for the indicated times (in minutes) at 37°C. Cell lysates
were prepared, resolved by SDS-PAGE, and immunoblotted with an anti-phospho-p42/44 ERK antibody. The same membranes were immuno-
blotted with anti-p42/44 antibody to control for total loading. (C) Cells added to the upper chamber were seeded in medium containing 0.1% BSA
and either 10 nM -Th or 50 M SFLLRN, and the number of invading cells was determined () as described in the legends to Fig. 1 and 2. Other
cells were pretreated with -Th or SFLLRN for 60 min at 37°C, agonists were removed, and the cells were washed with DMEM containing 0.5
U of hirudin/ml and then seeded in the upper chamber in medium containing only 0.1% BSA, and the number of invaded cells was determined
(/	). The data are expressed as the increase (n-fold; mean  SEM) in cellular invasion induced by agonists compared to untreated control cells
in at least three separate experiments.
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somes. A growing body of evidence suggests that multiple
signaling receptors remain ligand bound in endosomes (31).
Consequently, these active, endocytosed receptors are capable
of signaling, as many signaling effectors are found associated
with the endosomal compartment. Since proteolytic activation
of PAR1 by thrombin generates a tethered ligand (6), it is quite
conceivable that the tethered ligand remains bound to the
internalized receptor and continues to activate the receptor
even in an endosomal compartment. This could explain in part
the constitutive signaling observed in Hs578T cells that fail to
show significant recycling of the proteoytically activated PAR1
but show substantial signaling following activation and the
removal of thrombin. In any case, our findings clearly demon-
strate a link between altered PAR1 trafficking and sustained
signaling.
It has been shown that PAR1 is internalized via a dynamin-
and clathrin-dependent pathway and then sorted to lysosomes
(33). The sorting of GPCRs to recycling pathways or to lyso-
somes for degradation is likely determined by specific protein-
protein interactions. It was recently reported that sorting nexin
1 is involved in targeting activated PAR1 to lysosomes (38).
Whether defects in sorting nexins or other proteins that facil-
itate GPCR lysosomal sorting occur in invasive cells is not
known. It is also possible that activated PAR1 undergoes en-
docytosis through an alternate pathway that subverts lysosomal
sorting and leads to recycling instead. One such clathrin-inde-
pendent endocytic pathway that can subvert lysosomal sorting
is macropinocytosis. Macropinosomes are dynamic structures
with membrane components that likely recycle back to the cell
surface (32). Mutationally activated ras can induce macropi-
nocytosis, leading to the formation of large, irregular primary
endocytic vesicles by closure of lamellipodia generated at the
ruffling membrane (2). Interestingly, MDA-MB-231 cells har-
bor a constitutively active K-ras (G13D) mutant allele (12),
and these cells also contain unusually large endocytic vesicles,
suggesting the possibility that activated PAR1 is being inter-
nalized via macropinocytosis and recycled back to the plasma
membrane. Although ras mutations are not associated with the
majority of breast cancers, aberrant activation of Ras by over-
expression of receptor tyrosine kinases is seen in many breast
carcinomas (5) and thus may induce macropinocytosis and
perhaps aberrant PAR1 trafficking.
In conclusion, there is increasing evidence for the role of
aberrant GPCR signaling in human oncogenesis (18, 39). Pre-
vious studies have described activating mutations in GPCRs
and G subunits. More frequently, upregulation of ligand ex-
pression that promotes autocrine or paracrine mechanisms of
GPCR activation has been described for a variety of human
cancers. In this study, we report that a novel type of gain of
function in PAR1 signaling caused by dysregulated receptor
trafficking results in constitutive signaling that in turn contrib-
utes to and enhances cellular invasion. These studies provide
the first example of how aberrant trafficking may cause consti-
tutive GPCR activation to promote tumor cell invasion.
Whether dysregulated receptor trafficking is important for the
activation of other GPCRs involved in human cancer progres-
sion will be important to determine. The challenge now is to
elucidate the mechanisms responsible for the dysregulated
PAR1 trafficking that leads to constitutive receptor signaling.
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